Figure 7. IL-17 and miR-34a expression in human CRC.

(A and B) Human IL-17 enhances human colon organoids growth as shown by representative human colon organoids images (A) and quantitative organoids area (B). Error bars denote s.d. of triplicates. **p<0.01; p-value was calculated based on Student’s t-test. (C–F) RT-qPCR of colonic tumor and normal colon tissue samples from CRC patients (Figure 7—source data 1) comparing IL-17, RORC, IL-17RD, and miR-34a transcript levels. Dots refer to different samples, and lines connect the paired samples. Error bars denote s.e.m. of 17 normal and cancer samples. p-values were calculated based on paired t-test.

Figure 7—figure supplement 1. miR-34a targets human IL-6R, IL-17RD and CCL22.

(A) Western blot showing ectopic miR-34a expression suppresses human IL-6R expression. (B) Schematic representation of human IL-6r 3`UTRs containing the putative miR-34a binding sites. (C) Luciferase reporter assays confirming the miR-34a binding sites at 3`UTRs of human IL-6r. (D) Western blot showing ectopic miR-34a expression suppresses human CCL22 expression. (E) Schematic representation of human CCL22 3`UTRs containing the putative miR-34a binding sites. (F) Luciferase reporter assays confirming the miR-34a binding sites at 3`UTRs of human IL-6r. (G) Western blot showing ectopic miR-34a expression suppresses human IL-17RD expression. (H) Schematic representation of human IL-17rd 3`UTRs containing the putative miR-34a binding sites. (I) Luciferase reporter assays confirming the miR-34a binding sites at 3`UTRs of mouse IL-17rd. (J–L) Western blot and luciferase reporter assay showing human IL-23R is not targeted by miR-34a.